Fresh analysis indicates that patients who discontinue new weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle programs.
Findings released in a major medical journal shows that while obese people frequently drop substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"People buying these drugs should be informed of the risk of fast weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight within about a year and a half.
Comparing Approaches
The research, which looked at 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with other pills.
The team note that individuals who shed pounds through diet and exercise usually have a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Doctors suggest the mode of action of the injections explains the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in hunger is uncontrolled, making overeating a significant risk."
A Chronic Issue?
Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, considering the high risk of relapse, the treatment might need to be ongoing.
This opinion is echoed by pharmaceutical companies, who say that the findings "highlight the chronic character of obesity," similar to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the medication report a intense resurgence of hunger.
"It was like a switch flipping and you're instantly starving," said one woman.
This difficulty is worsened if individuals have not developed sustainable lifestyle or habit changes during treatment.
Growing Interest
Figures suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and long-term success likely depends on integrated lifestyle support.